Published Studies

Bacillus subtilis (HU58™)

4 weeks

Daily treatment with oral Bacillus subtilis HU58™ for 4 weeks was safe and well-tolerated in study subjects. HU58™ supported healthy blood ammonia levels.

DOI: 10.1155/2020/1463108

Bacillus subtilis (HU58™)

15 days

HU58™ reduced stool from 7-8 stools per day to 1-2 stools per day. Significant improvement was observed in 16 study subjects (scale 4), mild improvement observed in 6 study subjects (scale 5) and no improvement was observed in 8 study subjects (scale 6). HU58™ was safe, well-tolerated and effective in study subjects.

The Indian Practitioner, 73(4), 22-28.

Bacillus subtilis (HU58™)

8 weeks

Supplementation with 2 billion CFUs of Bacillus subtilis HU58™ was shown to support immune function and is well tolerated and safe for consumption in humans.

The Indian Practitioner, 70(9), 15-20.

MegaDuo™ (RestorFlora™)

2 weeks

MegaDuo™ was shown to support intestinal epithelial barrier function and immune function.DOI:

DOI:10.3390/microorganisms8071028

MegaDuo™ (RestorFlora™) and PreticX® Xylooligosaccharide (MegaPre™)
90 days

MegaDuo™ (RestorFlora™) and PreticX® Xylooligosaccharide (MegaPre™) were shown to support the body’s metabolic processes thereby promoting general health and wellbeing.

DOI: 10.1186/s12263-022-00718-7

Total Gut Restoration

in vitro (M-SHIME®)

Fecal samples were used in vitro to evaluate the effects on the gut microbiome using the Total Gut Restoration supplementation system. TGR supplementation resulted in short-chain fatty acids (SCFAs) production and supported intestinal barrier function and immune function.

DOI: suppl/10.2217/fmb-2022-0066

MegaSporeBiotic™ and MegaMucosa™

The combination of MegaSpore™ and MegaMucosa™ promoted immune function and provided support to colonic mucosa.

DOI: 10.3390/nu12123607

MegaSporeBiotic™

10 days

300 million CFU of MegaSporeBiotic™ supplementation supported immune function and iron levels in mice.

DOI:10.1002/jpen.1851

MegaSporeBiotic™

12 weeks

12 weeks of supplementation with MegaSporeBiotic™ supported triglyceride levels in study subjects.

PMID: 33041703

MegaSporeBiotic™

Administration of MegaSporeBiotic™ was shown to support liver function.

DOI: 10.3390/nu12030632

MegaSporeBiotic™

60 days

MegaSporeBiotic™ provided relief for occasional abdominal discomfort and supported elimination and digestive health in study subjects.

DOI: 10.3390/nu11091968

MegaSporeBiotic™

30 days

MegaSporeBiotic™ demonstrated cardiac-supportive and immune-supportive properties.

DOI:10.4291/wjgp.v8.i3.117

MegaSporeBiotic™ and MegaPre™

MegaSporeBiotic™ and MegaPre™ promoted microbial diversity in the transverse and descending colon. Additionally, this synbiotic combination promoted the production of all SCFAs in the gut, including acetate, propionate, and butyrate.

DOI:10.1016/j.ijpx.2019.100021

MegaSporeBiotic™

3 weeks

MegaSporeBiotic™ promoted bacterial diversity and supported ammonia, propionate, and lactate levels.

DOI:10.1016/j.foodres.2021.110676

MegaSporeBiotic™ and antibiotics

MegaSporeBiotic™ was shown to support immune system health and help maintain normal intestinal flora.

DOI:10.3390/microorganisms10061178

MyoMax™

8 Weeks

Randomized, double-blind, placebo-controlled trial. 26 participants. Supplementation with MyoMax™ was associated with a 12% increase in maximal cardiac output in aerobically trained athletes.

PMID: 28646812

MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™)

7/ 12 Weeks

Randomized, double-blind, placebo-controlled trial. 42 participants. 180 -360 mcg of vitamin K2 (MK-7) was shown to support bone health.

DOI:10.1017/S0007114511007185

MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™)

7/ 8 Weeks

Randomized, double-blind, placebo-controlled study. 60 participants. Vitamin K2 (MK-7) was well tolerated and displayed to support nerve function health.

The Ind. Pract. 2010; 63(5):287-291

MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™)

3 months

Open-labelled ambulant trial. 19 participants. MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™) was well tolerated and safe with a relief of occasional muscle cramps.

The Ind. Pract. 2010; 63(5):287-291

MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™)

In vitro. MK-7 is able to support immune function

DOI: 10.1089/jmf.2016.0030

MenaquinGold® Natural MK (MyoMax™, MegaQuinD3™, MegaQuinone™)

7/ 8 weeks

Open-labeled observational study. 100 participants. Vitamin MK-7 was well tolerated and displayed to support nerve function health.

DOI: 10.4103/jpp.JPP_72_18

FidoSpore™

30 days

Spore-based probiotics support digestive health in dogs.

DOI: 10.3390/ani11051367

MegaSporeBiotic™

8 weeks

Single-blinded, 25 participants. Probiotic supplementation helped retain moisture in skin. Probiotic supplementation supports skin health in those with skin issues & improved complexion for those with skin issues. Placebo for the first 4 weeks, followed by 4 weeks of probiotic supplementation.

DOI:10.3390/jcm12030895

Pylopass® (PyloGuard™)

28 days and 56 days

Placebo-controlled trial 103, participants, children 9-17 years. Supported ammonia levels in Pylopass® (PyloGuard™) group. Pylopass® (PyloGuard™) group reported higher rate of abdominal relief and reduced incidence of diarrhea

DOI: 10.15406/ghoa.2020.11.00407

Pylopass® (PyloGuard™)

2 weeks

Pilot study 27 participants. DSM17648 co-aggregates with human strain of H. pylori without aggregating with any other commensal bacteria. Supplementation supported levels of H. pylori.

DOI: 10.1007/s12602-014-9181-3

Pylopass® (PyloGuard™)

4 weeks

Placebo-controlled, single-blind study 24 participants. Supported H.pylori levels and improvement of abdominal discomfort

DOI: 10.1186/s40795-018-0257-4

Pylopass® (PyloGuard™)

2 weeks

Bifidobacterium longum

1714® (Zenbiome Cope™ & Sleep™)

4 weeks

Placebo-controlled study. 22 participants. 1714® strain supported cortisol levels and reduced perceived stress levels throughout the study compared to the placebo group. Significantly lower perceived stress levels in those participants taking B. longum 1714® compared to the placebo group. Bifidobacterium longum 1714® (Zenbiome Cope™ & Sleep™)

DOI: 10.1038/tp.2016.191

Bifidobacterium longum

1714® (Zenbiome Cope™ & Sleep™)

4 weeks

Randomized, double-blinded, placebo-controlled trial. 40 participants. 1714® strain supported relaxation reduced stress, and enhanced mood Difference of neural activity change during resting state in theta band after 1714®- promoted theta brainwave activity at rest, compared to the placebo group. Difference of neural activity change during resting state in beta 2 band after 1714® supported body’s adaptation to beta 2 brain wave activity at rest, compared to the placebo group.

DOI: 10.14309/ajg.0000000000000203

Bifidobacterium longum

1714® (Zenbiome Cope™ & Sleep™) 4 weeks

Double-blind, randomized, placebo-controlled, repeated measures, cross-over design. 20 participants. Overall sleep quality and duration of sleep improved significantly in the probiotic treated group during exam stress compared with the placebo treated group.

DOI: 10.1016/j.bbih.2020.100174

Bifidobacterium longum 1714® and Bifidobacterium longum 35624® (Zenbiome Cope™ & Sleep™)

8 weeks

Open label exploratory study. 40 participants. This exploratory open-label study found that 82% of subjects had significantly improved issues after 8 weeks, with 66% of subjects significantly improving after 4-weeks (issue severity score change of ≥ 50) in the moderate to severe group. The combination solution improved each of the individual issues (occasional abdominal discomfort, distension, bowel satisfaction), as well as an improvement in their quality of life. Participants in this group also had a significant improvement in their morning cortisol awakening response, a physiological biomarker of stress, after 4-weeks.

DOI: 10.1111/nmo.14477